戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ioxide emission in cancer patients receiving amifostine.
2 ted in the presence of the antioxidant agent amifostine.
3 oprotector to become available clinically is amifostine.
4 ding the activity of dexrazoxane, mesna, and amifostine.
5  involved in the radioprotective efficacy of amifostine.
6    Median saliva production was greater with amifostine (0.26 g v 0.10 g, P=.04).
7                                              Amifostine: (1) Amifostine may be considered for the red
8         Mice received once-daily dosing with amifostine (10-100 mg/kg, intraperitoneal injection) 3 d
9     To evaluate the hematological effects of amifostine, 18 patients with myelodysplastic syndrome (M
10                             With and without amifostine, 2-year local-regional control, disease-free
11 xrazoxane, three reports (two studies) each; amifostine, 33 reports (31 studies); and mesna, no publi
12    Following chemotherapy, patients received amifostine (340 mg/m2 4 days a week for 5 weeks, or 200
13                                   When used, amifostine (600 mg/m(2)/dose) was administered as a bolu
14 aclitaxel 175 mg/m2 over 3 hours followed by amifostine 740 mg/m2 and cisplatin 75 mg/m2 administered
15                            Patients received amifostine (740 or 910 mg/m2) followed by cisplatin (120
16 2) and cisplatin (100 mg/m2) with or without amifostine (910 mg/m2) every 3 weeks for six cycles.
17                             We conclude that amifostine administered at doses </=200 mg/m2 three time
18                                              Amifostine administered before and during the cisplatin
19         This study tested effects of chronic amifostine administration on parameters of oxidative str
20 d over 90 minutes beginning 15 minutes after amifostine administration.
21 ts were randomly assigned at registration to amifostine (AM) 500 mg IV four times per week or no AM d
22           Patients were randomly assigned to amifostine (AM) or no AM during chemoradiotherapy.
23                                              Amifostine, an organic thiophosphate, has demonstrated t
24 athologic tumor response rates were 37% with amifostine and 28% in controls, with comparable median s
25 g biomarkers for radioprotective efficacy of amifostine and other countermeasures under development.
26                                In agreement, amifostine and WR-1065 coincubation reduced uptake in BN
27 -protectant activity-dexrazoxane, mesna, and amifostine-and questions about the role of these protect
28                                              Amifostine appears to reduce cisplatin-related nephrotox
29                               Treatment with amifostine at 200 mg/kg prior to irradiation seemed to i
30                                              Amifostine attenuates oxidative stress and improves lipo
31                            Pretreatment with amifostine before each cycle of chemotherapy resulted in
32                                              Amifostine can be administered safely with high-dose cis
33 ese findings show that the administration of amifostine causes metabolic shifts that would provide an
34 oxic drugs, we conducted a phase II trial of amifostine, cisplatin, and vinblastine (ACV) in patients
35  CA20948 tumor-bearing rats, with or without amifostine coadministration, via several routes.
36 ography-mass spectrometry confirmed that the amifostine conversion to WR-1065 was significantly more
37      This randomized trial evaluated whether amifostine could ameliorate these side effects without c
38      This study was designed to determine if amifostine could reduce the serious toxicities associate
39  findings shed new light on the mechanism of amifostine cytoprotection and encourage clinical researc
40                          Coadministration of amifostine decreased renal uptake of radiolabeled octreo
41                                              Amifostine did not reduce mucositis.
42                                              Amifostine doses less than or equal to 200 mg/m2 were we
43 e, David Brizel, who worked on the phase III amifostine efficacy study, and Jens Overgaard, a vehemen
44                              The aminothiol, amifostine (Ethyol; U.S. Bioscience, West Conshohocken,
45 ifty-three percent of the patients receiving amifostine had at least one episode of nausea and/or vom
46 e and survival data provide no evidence that amifostine impairs response to treatment.
47 hat were corrected in part by treatment with amifostine in a drug-dose dependent manner.
48 efractory cytopenias received treatment with amifostine in a Phase I/II study.
49 lines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled on clinical
50                                     Although amifostine in vitro did not inhibit the activity of the
51 patients (16%) required early stopping of an amifostine infusion due to hypotension.
52                                              Amifostine is a promising selective radioprotector for n
53 tration-approved therapies for ARS; whereas, amifostine is limited to treating low dose (0.7-6 Gy) ra
54                                              Amifostine is the prototype drug.
55                       WR-2721, also known as amifostine, is a well-known radioprotector, but has sign
56                                              Amifostine may be considered for prevention of cisplatin
57                              Amifostine: (1) Amifostine may be considered for the reduction of nephro
58 amifostine to its active metabolite WR-1065, amifostine may not only protect in multiple ways normal
59 clinical and clinical studies that suggested amifostine may potentiate the effects of cytotoxic drugs
60 nerally reversible and the data suggest that amifostine may protect against long-term renal insuffici
61                                              Amifostine may provide renal protection during PRRT usin
62                               The effects of amifostine on human basal metabolism, mouse liver metabo
63    This study describes the direct effect of amifostine on kidney and tumor uptake of (111)In-DOTA,Ty
64           This study examines the effects of amifostine on the metabolic profiles in tissues of mice
65                                    Moreover, amifostine opponents argue that the evidence is insuffic
66 g BN-16 cells, in the absence or presence of amifostine or its active metabolite WR-1065.
67 r percent of CP patients compared with 9% of amifostine plus CP patients discontinued therapy because
68                                              Amifostine preconditioning activates lung tissue antioxi
69  mg/m2) was given weekly for 5 weeks with no amifostine pretreatment.
70                                              Amifostine prevented the development of MMC-induced PVOD
71                                              Amifostine prevents MMC-induced PVOD in rats and should
72                                    In vitro, amifostine promotes the formation and survival of primit
73 ioprotection was observed through the use of amifostine prophylaxis of ARS.
74                     The cytoprotective agent amifostine protected rats from long-term nephrotoxicity
75                                              Amifostine protects normal cells from DNA damage inducti
76                                              Amifostine reduced acute and chronic xerostomia.
77                                              Amifostine reduced grade > or =2 acute xerostomia from 7
78                            Pretreatment with amifostine reduces the cumulative hematologic, renal, an
79                           Preincubation with amifostine reversed the high-glucose effects.
80                                              Amifostine's level of activity in this trial was insuffi
81                                              Amifostine selectively protects NCTC cells against radia
82 mised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram,
83 e adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram,
84                                              Amifostine, sodium diethyldithiocarbamate, and disulfira
85                                              Amifostine, sodium diethyldithiocarbamate, and intratymp
86 at the thiol form of the cytoprotective drug amifostine that is designated WR-1065 [2-((aminopropyl)a
87 , and Jens Overgaard, a vehement opponent of amifostine therapy, provide thought-provoking arguments
88 venous treatment with 100, 200, or 400 mg/m2 amifostine three times a week, or 740 mg/m2 weekly for t
89 lga Spirulina platensis as a microcarrier of Amifostine to construct an oral delivery system.
90 d cancer cells in their abilities to convert amifostine to its active metabolite WR-1065, amifostine
91 r response, some institutions are now adding amifostine to their chemoradiation regimens.
92 in bone marrow, jejunum, and lung samples of amifostine-treated and saline-treated control mice.
93 4.5%; one-sided chi(2) test P = .005) of the amifostine-treated patients had at least grade 3 ototoxi
94 r increase in absolute neutrophil count with amifostine treatment (range, 426 to 11,348/microL).
95             A return to baseline levels with amifostine treatment occurred for these pathways within
96 solution immunofluorescence microscopy) that amifostine treatment supports DSB repair in gamma-irradi
97                                              Amifostine was administered (200 mg/m(2) intravenous) da
98                                              Amifostine was administered intravenously 3 times a week
99                 The metabolomic signature of amifostine was also evaluated in mice as a model for rad
100                                              Amifostine was generally well tolerated; the principal s
101                                              Amifostine was well-tolerated.
102                  These protective effects of amifostine were associated with increased superoxide dis
103 o highly responsive to protective effects of amifostine, while jejunum and lung showed only modest ch
104 n patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (def
105                             The mechanism of Amifostine (WR-2721) mediated radioprotection is poorly
106 rpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically
107 trated lower swallowing dysfunction AUC with amifostine (z test P = .025).

 
Page Top